Clinical Trial Update: Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab [Phase 2]

View source ↗

Summary

Phase 2 trial update on optimized donor selection with nonmyeloablative bone marrow transplant using post-transplant cyclophosphamide and rituximab for B-cell l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Chronic Lymphocytic Leukemia
• Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Rituximab (rituximab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Lymphoma, B-cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2018-07-24